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Postprandial Hyperglycemia and
Cardiovascular Disease
Is the HEART2D study the answer?
I
n the recent HEART2D (Hyperglyce-
mia and its Effect After Acute Myocar-
dial Infarction on Cardiovascular
Outcomes in Patients with Type 2 Diabe-
tesMellitus)study,publishedinthisissue
of Diabetes Care, Raz et al. (1) try to an-
swer a hotly debated question of the last
10 years: is postprandial hyperglycemia
an independent risk factor for cardiovas-
cular disease in diabetes? This question,
highlighted recently, has arisen because
of the identiﬁed linear relationship,
widely conﬁrmed in many studies, be-
tween the risk of cardiovascular disease
death and 2-h oral glucose tolerance test
values (2). Consistent with these past
results, a recent study has conﬁrmed
postprandial hyperglycemia as an inde-
pendentriskfactorforcardiovasculardis-
ease in type 2 diabetes (3). At the same
time, in the STOP-NIDDM Trial it has
been shown, as a predeﬁned secondary
end point, that treating postprandial hy-
perglycemia may reduce the incidence of
new cardiovascular events in people with
impairedglucosetolerance(4)—aﬁnding
conﬁrmed in type 2 diabetes by a meta-
analysis on the use of acarbose (5).
Another important issue is that pran-
dial glucose regulation, an emerging
approach to treating type 2 diabetes, em-
phasizes the need for moderating the
acute surges in plasma glucose levels that
follow meals (6). Mechanistic and epide-
miological studies indicate that postpran-
dial glucose signiﬁcantly contributes to
overall glycemic exposure (6). In particu-
lar, postprandial hyperglycemia is the
most important contributor to A1C, par-
ticularly when it is lower than 7.5% (7).
Therefore, targeting postprandial hyper-
glycemiaisimportantfortheachievement
of A1C targets. Numerous prandial ther-
apeutics are now available, and an ever-
growing literature on their use shows that
they are safe, effective, and convenient
and that they may offer distinct clinical
beneﬁts not found with treatments that
target basal (fasting) glycemia (8–9). The
International Diabetes Federation has re-
cently recognized, in speciﬁc guidelines,
the signiﬁcance of postprandial hypergly-
cemiaandtheneedtomeasureandtreatit
(8–9). In these guidelines, the cutoff for
postprandial hyperglycemia is indicated
as 7.8 mmol/l (140 mg/dl)—a value
which, as has recently been shown, nor-
mal healthy people never attain (10).
The HEART2D study does not show
any beneﬁcial effect of treating postpran-
dialhyperglycemiainreducingcardiovas-
cular events in diabetic patients at very
high risk for more cardiovascular events.
It is, however, important to take into ac-
count that the patients were enrolled
within 21 days of hospital admission for a
recent acute myocardial infarction. Is the
result of this study surprising? Given the
recent lessons from the ACCORD trial
(11), ADVANCE study (12), and long-
term follow-up of the UK Prospective Di-
abetes Study (13), I believe that the
negative result of the HEART2D study is
just in line with these studies: if the con-
trol of hyperglycemia (either fasting
[ACCORD and ADVANCE] or postpran-
dial [HEART2D]) is started too late, the
possiblebeneﬁcialeffectoftreatinghyper-
glycemia (either fasting [UK Prospective
Diabetes Study] or postprandial [STOP-
NIDDM]) in a very early stage of the dis-
ease is lost.
It may be that several aspects of the
HEART2D study can be criticized. The
study is clearly underpowered, and this is
conﬁrmed by the low rate of the events.
Otherwise, the patients were very well
treated for cardiovascular disease. As re-
ported by the authors, “the frequency of
concomitant cardiovascular drug use was
high and similar between groups (pran-
dial vs. basal: 95.0 vs. 95.9%; P 
0.478).” This means that, as learned from
the ACCORD and ADVANCE studies, if
ononehandwecanbehappybecausethe
patients seem to be very well treated to-
day, on the other hand this also implies
that the calculation of sample size for the
studies in the ﬁeld of cardiovascular dis-
easeanddiabetesmustberevisedinorder
to get real information. Another impor-
tant issue is the failure of the study to
reach the predetermined difference in
postprandial hyperglycemia of 2.5
mmol/l: the mean difference at the end of
the study was only 0.8 mmol/l, which,
though a signiﬁcant difference between
the two groups, is less than one-third of
the goal. Some interesting points emerge
from consideration of these data. The dif-
ference seems to be too small to inﬂuence
so hard an outcome, particularly in a very
short period. This point of view is sus-
tained by recent evidence suggesting why
the beneﬁts of reducing blood glucose
levels on macrovascular outcomes take so
much longer to appear in type 2 versus
type1diabetes.Additionalevidencefrom
an earlier study conducted over 18 years
ago shows that the contribution of hyper-
glycemia to CVD risk is much greater in
type 1 than in type 2 diabetes, due to
other risk factors present in these pa-
tients. A 1% increase in A1C was associ-
ated with a 50% increase in CVD risk
for patients with type 1 diabetes com-
pared with a 7.5% increase for patients
with type 2 diabetes (14,15). This, in my
opinion,impliesthatthecontrolofhyper-
glycemia is important for the preven-
tion of cardiovascular complications in
diabetes, but to show this effect takes
time and, of course, it would be more
evident if there were a larger difference
between the values of glycemia over
time.
However, the real source of worry is
theevidencethatcontrollingpostprandial
hyperglycemia is difﬁcult. I think we can
say that control of hyperglycemia—any
kind of hyperglycemia, be it fasting or
postprandial—is still a difﬁcult task, as
learnedfromtherecenttrials,particularly
from the Steno-2 (16), and also from the
HEART2D.Inthisstudy,attheendpoint,
the mean A1C was 7.7% in the prandial
group and 7.8% in the basal, and only
28% of the patients in the prandial group
and 31% in the basal group achieved an
A1C7.0%.Thesituationforfastinggly-
cemia seems no different: 8.1  0.2
mmol/l prandial vs. 7.0  0.2 mmol/l
basal.
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other lesson consistent with evidence
from the recent trials: starting the control
of hyperglycemia when established car-
diovasculardiseaseisalreadypresentcan-
not have a beneﬁcial effect on the
progression of this kind of complication
of diabetes. At the same time, we have
again learned how difﬁcult optimal con-
trol of hyperglycemia is—a goal that
seems to be mandatory at a very early
stage of diabetes.
In conclusion, the HEART2D study
has just conﬁrmed these two aspects of
the management of diabetes but certainly
has not answered the key question:
whetherpostprandialhyperglycemiaisan
independentriskfactorforcardiovascular
complications in diabetes. Surely, I won-
der whether the results would have been
different if the study had used other post-
prandial drugs in addition to insulin to
achieve goal (e.g., acarbose or pramlint-
ide,whichareapprovedwithinsulin)and
whether the study will be repeated with
newer drugs that more effectively lower
postprandial glucose, such as GLP-1 ago-
nists or DPP-4 inhibitors (8). Finally,
maybe we will receive more information
from two studies that are still ongoing: 1)
the NAVIGATOR (Nateglinide And Val-
sartan in Impaired Glucose Tolerance
Outcomes Research) trial (17), which
uses nateglinide and has already been
prolonged because of a low rate of events,
and 2) the ACE (Acarbose Cardiovascular
Evaluation) trial, which is a large study
beingperformedinChina.However,both
of these studies are, again, in people with
impaired glucose tolerance and at high
risk for cardiovascular disease.
Nevertheless, although the key
question of whether postprandial hy-
perglycemia is really a risk factor for
cardiovascular disease is still open, I be-
lieve that implementing strategies aiming
to lower postprandial hyperglycemia in
clinicalpracticeremainsagoodtherapeu-
tic choice because it seems the best ap-
proach to reach recommended A1C
targets (8–9). And this is always very
good for our patients.
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